- AstraZeneca stock tumbled as much as 7% on Monday following reports that the drugmaker had been in early talks with Bristol Myers Squibb about joining forces.
- AstraZeneca investors balked at the reported $400 billion Bristol Myers tie-up, leading to a significant drop in its stock price.
- Bristol Myers Squibb stock rose 6% in U.S. premarket trading amid the merger talks.
- AstraZeneca's market capitalization stood at $264 billion before the reports, while Bristol Myers Squibb's was approximately $133 billion.
- AstraZeneca shares were down 4.8% at 1122 GMT, marking the second-biggest drop on the FTSE 100 index.
- The potential merger could create a company valued at nearly $400 billion, making it one of the largest deals in pharmaceutical history.
- Analysts expressed confusion over the merger talks, noting AstraZeneca's strong growth and innovation profile.
- Antitrust scrutiny is expected due to the overlapping oncology portfolios of both companies.
- AstraZeneca's oncology franchise generated around $25 billion last year, representing close to half of its overall revenue.
AstraZeneca's stock dropped 7% on reports of merger talks with Bristol Myers Squibb, which rose 6% in premarket trading. The potential merger, valued at $400 billion, could create the world's largest drugmaker by revenue. However, analysts express skepticism about the strategic necessity of such a deal.7
AstraZeneca's market capitalization was approximately $264 billion before the news, while Bristol Myers stood at $133 billion. The combined entity would rank among the most significant pharmaceutical mergers in history. Jefferies analysts noted, "If there is one company that doesn't need financial engineering, it's AstraZeneca," highlighting the company's strong growth and innovation profile.45
Despite the potential financial benefits, many investors are wary. Lucy Coutts, an investment director at JM Finn, stated, "On balance, BMS shareholders would be the winners of any combination with AZN and so this news will undoubtedly be received coolly by AZN shareholders."
The merger could face antitrust scrutiny due to overlapping oncology portfolios, with AstraZeneca's oncology franchise generating around $25 billion last year, nearly half of its total revenue. Markus Manns, a portfolio manager at Union Investment, remarked, "A combination with Bristol does not make strategic or financial sense," emphasizing concerns over disrupting AstraZeneca's well-managed pipeline.910
As AstraZeneca seeks to expand its U.S. footprint, the company has invested significantly in U.S. manufacturing and has close ties with the current administration. However, analysts remain puzzled by the merger talks, questioning the need for such a transformative acquisition given AstraZeneca's robust position in the market.
““Given the strength of AZ's growth and innovation profile, we are a bit perplexed,” Jefferies analysts wrote Monday. CEO Pascal Soriot has targeted $80 billion in annual revenue by 2030, and a combined firm could face antitrust scrutiny over oncology overlaps.”
qz.com
